CARP and CanniMed Announce Partnership to Educate Canadians About Medical Cannabis

TORONTO, Sept. 10, 2015 /CNW/ – CARP, Canada’s largest non-profit, non-partisan advocacy association for Canadians As We Age, has announced a new “CARP Recommended” partnership with CanniMed Ltd., an industry leader in providing Canadians with access to a standardized, safe and trusted supply of pharmaceutical-grade cannabis under the Marihuana for Medical Purposes Regulations (MMPR), governed by Health Canada.

Medical cannabis has been used to treat symptoms associated with a significant number of medical conditions. Many of these surface in, and are felt by, people as they age: ‎arthritis, insomnia, glaucoma, nausea, chronic or neuropathic pain, as well as side effects related to cancer therapy, to name a few.

As this new therapeutic industry takes shape in Canada, inaccurate and misleading information can be very detrimental to patients’ health and wellbeing. Accordingly, the CARP/CanniMed Partnership endeavours to provide straightforward and accurate information for people who are exploring the use of cannabis as a medicine.

“At CanniMed, we take our role as educator and facilitator very seriously,” said Brent Zettl, President and CEO, CanniMed Ltd. “This partnership with CARP will help to disseminate accurate medical cannabis information to a patient demographic that is highly engaged in learning more on how people with chronic and terminal illnesses can improve their quality of life when conventional medicine just isn’t enough.”‎

“Zoomers are aware that they are responsible for their own health, and are asking about medical cannabis. After surveying the market carefully, we can confidently recommend CanniMed,” said CARP President Moses Znaimer, “for its singular devotion to science based medical cannabis, while many other producers have their eyes on the recreational market.”

Under the “CARP Recommended” Partnership, CARP members have access to a unique online portal for information – as well as a dedicated customer service team, including CanniMed’s staff pharmacist, to support patients in determining if medical cannabis is an appropriate option for their particular condition, and to help select the most appropriate product for patients’ needs.

Medical cannabis became available to Canadians in 2001. Thousands of Canadians rely on medical cannabis for symptom treatment. The only legal source of such medical cannabis inCanada is through a Licensed Producer, who in turn requires a signed medical document (prescription) from a healthcare practitioner.

For more information on “How To Talk To Your Doctor About Medical Cannabis”, see the educational supplement on pages 30/31 in the October issue of Zoomer magazine.

For more information, please visit:


CARP is Canada’s largest national non-profit, non-partisan organization whose mission is to enhance the quality of life for Canadians As We Age. CARP has over 300,000 members, a network of 60 chapters across Canada, and is on a “March to a Million” membership campaign. Most CARP members also receive 9 issues of ZOOMER magazine. For more info, please visit


CanniMed Ltd., and its parent company, Prairie Plant Systems, have a long history in the production of medical cannabis. The company was the sole supplier to Health Canada under the former medical marijuana program from 2001-2013, and more recently was the first producer to be licensed under the new Marihuana for Medical Purposes Regulations(MMPR).

The company’s primary focus is on patient safety by growing and manufacturing medical cannabis products that are safe and consistent, following a 281 point quality control process.


Image with caption: “CARP (CNW Group/CARP)”. Image available at:

Image with caption: “CanniMed Ltd. (CNW Group/CARP)”. Image available at:

CONTACT: Media Contacts: For CARP: Leanne Wright, 416.886.6873, [email protected]; For CanniMed: Dara Willis, 416.836.9272, [email protected]


The post CARP and CanniMed Announce Partnership to Educate Canadians About Medical Cannabis appeared first on MJI News.